Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and the promise of “programmable,” precision medicine for patients, speakers at Bio Korea 2026 said April 28.
BioWorld Asia Analysis and data insight Clinical Conferences Regulatory Cardiovascular Endocrine/metabolic Neurology/psychiatric Antisense RNAi Asia-Pacific U.S. BLA FDA